GlycoMimetics, Inc.

NasdaqGM:GLYC Stock Report

Market Cap: US$205.0m

GlycoMimetics Future Growth

Future criteria checks 0/6

GlycoMimetics is forecast to grow earnings and revenue by 59.3% and 57.4% per annum respectively while EPS is expected to grow by 63.4% per annum.

Key information

59.3%

Earnings growth rate

63.4%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate57.4%
Future return on equityn/a
Analyst coverage

Low

Last updated28 Mar 2024

Recent future growth updates

Recent updates

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Mar 20
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Nov 19
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Jan 30
Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

Oct 06
Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics has a new Chief Medical Officer

Sep 06

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

Aug 03

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

Jun 04
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Mar 16

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Nov 20
Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Aug 20
We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12
Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19
GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24
GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28
How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

The Investment Case For GlycoMimetics

Nov 17

Earnings and Revenue Growth Forecasts

NasdaqGM:GLYC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202686-50-45N/A4
12/31/202535-32-47-23
12/31/2024N/A-41-37-364
12/31/20230-37-35-35N/A
9/30/2023N/A-38-35-35N/A
6/30/2023N/A-37-35-35N/A
3/31/20230-42-44-44N/A
12/31/20220-47-47-46N/A
9/30/20220-54-51-51N/A
6/30/20220-63-60-60N/A
3/31/20220-64-57-57N/A
12/31/20211-63-58-57N/A
9/30/20211-62-54-54N/A
6/30/20212-58-49-49N/A
3/31/20212-58-50-50N/A
12/31/202010-51-39-39N/A
9/30/202010-50-42-42N/A
6/30/20209-50-44-44N/A
3/31/20209-51-41-41N/A
12/31/2019N/A-58-52-52N/A
9/30/2019N/A-57-49-49N/A
6/30/2019N/A-55-46-46N/A
3/31/2019N/A-51-48-47N/A
12/31/2018N/A-48-43-43N/A
9/30/2018N/A-44-42-42N/A
6/30/2018N/A-40-38-38N/A
3/31/2018N/A-37-31-31N/A
12/31/2017N/A-33-30-30N/A
9/30/2017N/A-32N/A-27N/A
6/30/20170-32N/A-29N/A
3/31/20170-32N/A-30N/A
12/31/20160-32N/A-30N/A
9/30/20160-32N/A-31N/A
6/30/20160-32N/A-10N/A
3/31/201620-13N/A-9N/A
12/31/201520-13N/A-8N/A
9/30/201520-11N/A-7N/A
6/30/201520-11N/A-26N/A
3/31/201515-13N/A-10N/A
12/31/201415-11N/A-4N/A
9/30/201415-8N/A-4N/A
6/30/201415-5N/A-2N/A
3/31/20140-16N/A-14N/A
12/31/20134-11N/A-16N/A
9/30/20138-6N/A-13N/A
6/30/201312-2N/A-12N/A
3/31/2013153N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GLYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GLYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GLYC is forecast to have no revenue next year.

High Growth Revenue: GLYC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GLYC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.